Skip to main
INSP
INSP logo

INSP Stock Forecast & Price Target

INSP Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 38%
Buy 33%
Hold 25%
Sell 4%
Strong Sell 0%

Bulls say

Inspire Medical Systems has demonstrated strong growth dynamics, with Q4 revenue reaching $239.7 million, reflecting a 24.5% year-over-year increase, while earnings per share of $1.15 surpassed consensus expectations of $0.73. The company has seen a notable rise in therapy utilization, increasing from 1.1 procedures per month in 2021 to 1.8 in 2024, indicating enhanced adoption of their neurostimulation technology for obstructive sleep apnea. Furthermore, Inspire is well-positioned for future growth, supported by expansion initiatives, increasing procedure efficiencies, and innovative product launches, which collectively suggest significant potential for revenue enhancement and market penetration.

Bears say

Inspire Medical Systems faces a negative outlook due to several concerning factors, including a projected lower earnings per share (EPS) estimate decrease from $2.41 to $2.22 for 2025, despite being above street expectations. The firm's revenue growth appears stagnant, with sales estimates for 2025 of $945 million being only modestly above the previous year's guidance and underperforming compared to management's outlined targets. Additionally, a downside scenario factors in risks related to slower market penetration, reduced patient utilization, delayed pathways to profitability, and potential competition, which could further hinder Inspire's long-term growth prospects.

INSP has been analyzed by 24 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 33% recommend Buy, 25% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inspire Medical Systems Inc (INSP) Forecast

Analysts have given INSP a Buy based on their latest research and market trends.

According to 24 analysts, INSP has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $186.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $186.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inspire Medical Systems Inc (INSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.